MedTrace Logo

Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis

NCT03413618 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-02-04

Study results available
· View outcomes & findings →

Summary

The randomized clinical study aimed to assess the efficacy and safety of standard anticoagulation with rivaroxaban in combination with diosmin compared to the isolated use of standard rivaroxaban for prolonged therapy of acute femoro-popliteal deep vein thrombosis reflected the speed of deep vein recanalization and incidence of post-thrombotic syndrome.

Conditions

  • Deep Vein Thrombosis
  • Postthrombotic Syndrome

Interventions

DRUG

Rivaroxaban

15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month

DRUG

Diosmin

600 mg q.d. for 12 month

OTHER

compression stockings

above knee stocking for 12 month

Sponsors & Collaborators

  • Pirogov Russian National Research Medical University

    lead OTHER

Principal Investigators

  • Ilya Schastlivtsev, PhD · Pirogov Russian National Research Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-20
Primary Completion
2019-07-31
Completion
2019-07-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03413618 on ClinicalTrials.gov